Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huoxiang Zhengqi Granules is a traditional Chinese patent medicine (CPM) formulation used to treat gastrointestinal disorders, particularly those characterized by 'dampness' and 'summer-heat' in Traditional Chinese Medicine (TCM). The formula is a complex mixture of herbs, typically including *Agastache rugosa*, *Atractylodes lancea*, *Citrus reticulata*, *Magnolia officinalis*, *Platycodon grandiflorus*, *Poria cocos*, and *Glycyrrhiza uralensis*. It is commonly indicated for gastrointestinal flu, heatstroke, and acute gastritis. During the COVID-19 pandemic, Huoxiang Zhengqi Granules was included in Chinese national treatment guidelines and evaluated in clinical registry studies (such as ChiCTR2200059413) for the management of mild COVID-19 symptoms, focusing on its potential to improve recovery rates and viral clearance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huoxiang Zhengqi Granules.